公开(公告)号：US20240254258A1

公开(公告)日：2024-08-01

申请号：US18545533

申请日：2023-12-19

申请人： Trellis Bioscience, Inc.

发明人： Angeles Estelles ,  Mikhail Gishizky ,  Stefan Ryser ,  Lawrence Kauvar

IPC分类号： C07K16/40 ,  A61K9/16 ,  A61K39/00 ,  A61K47/68

CPC分类号： C07K16/40 ,  A61K9/1617 ,  A61K47/6817 ,  A61K47/6871 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

摘要： Disclosed herein are monoclonal antibodies, and antigen-binding fragments thereof, that immunospecifically bind to human Anaplastic Lymphoma Kinase (ALK). Also provided are methods of use thereof, such the treatment of cancer. Also included are antibody-drug conjugates (ADCs) including the monoclonal antibodies and/or antigen-binding fragments thereof, linked to an effector agent, such as a cytotoxic agent. Also provided are method of using such ADCs. Nucleic acid molecules, vectors, and host cells for the monoclonal antibodies and antigen-binding fragments thereof are also provided, as are pharmaceutical and veterinarian compositions including the monoclonal antibodies, and antigen-binding fragments thereof, and/or the associated ADCs.

公开(公告)号：US20240228664A9

公开(公告)日：2024-07-11

申请号：US18357007

申请日：2023-07-21

申请人： Bristol-Myers Squibb Company

发明人： Lin Hui Su ,  Ekaterina Deyanova ,  Burce Ergel Gurbuzbalaban ,  Mariana Nacht ,  Samantha Elaine Pace ,  Yun Wang ,  Qing Xiao ,  Ramakrishna Chandran ,  Shailesh Dudhgaonkar ,  Michael Louis Doyle ,  Michael Gilman ,  Richard Huang ,  Akbar Nayeem ,  Alok Sharma ,  Qihong Zhao

IPC分类号： C07K16/40 ,  A01N1/02 ,  A61K45/06 ,  A61K47/68 ,  A61K49/00 ,  A61P19/02 ,  A61P37/06

CPC分类号： C07K16/40 ,  A01N1/0226 ,  A61K45/06 ,  A61K47/6871 ,  A61K49/0002 ,  A61P19/02 ,  A61P37/06

摘要： The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.

公开(公告)号：US20240216521A1

公开(公告)日：2024-07-04

申请号：US18382896

申请日：2023-10-23

申请人： IMMUNOGEN, INC.

发明人： Scott A. Hilderbrand ,  Daniel F. Milano

IPC分类号： A61K47/68 ,  A61K31/5365 ,  A61K31/537 ,  A61K31/5513 ,  A61K31/5517 ,  C07K16/28 ,  C07K16/40

CPC分类号： A61K47/6803 ,  A61K31/5365 ,  A61K31/537 ,  A61K31/5513 ,  A61K31/5517 ,  A61K47/6849 ,  A61K47/6871 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/40

摘要： The present invention provides methods of preparing a cell-binding agent-cytotoxic agent conjugate comprising a cell-binding agent (CysCBA) having one or more unpaired cysteine residues covalently linked to a cytotoxic agent. Also provided are conjugates prepared by the methods described herein and pharmaceutical composition and methods of use thereof.

公开(公告)号：US11833214B2

公开(公告)日：2023-12-05

申请号：US16825127

申请日：2020-03-20

申请人： IMMUNOGEN, INC.

发明人： Scott A Hilderbrand ,  Daniel F. Milano

IPC分类号： C07K16/40 ,  A61P35/00 ,  A61K47/68 ,  A61K31/5365 ,  A61K31/537 ,  A61K31/5513 ,  A61K31/5517 ,  C07K16/28

CPC分类号： A61K47/6803 ,  A61K31/537 ,  A61K31/5365 ,  A61K31/5513 ,  A61K31/5517 ,  A61K47/6849 ,  A61K47/6871 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/40

摘要： The present invention provides methods of preparing a cell-binding agent-cytotoxic agent conjugate comprising a cell-binding agent (CysCBA) having one or more unpaired cysteine residues covalently linked to a cytotoxic agent. Also provided are conjugates prepared by the methods described herein and pharmaceutical composition and methods of use thereof.

公开(公告)号：US11827718B2

公开(公告)日：2023-11-28

申请号：US17325085

申请日：2021-05-19

申请人： University of Kentucky Research Foundation

发明人： Susan D. Kraner ,  Rodney P Guttmann ,  Christopher M. Norris ,  Jenna Leigh Gollihue

IPC分类号： C07K16/40 ,  C12N15/85 ,  A61K47/68

CPC分类号： C07K16/40 ,  A61K47/6871 ,  C12N15/85 ,  C07K2317/64 ,  C12Y301/03016

摘要： Provided herein are antibodies, or antigen-binding portions thereof, which specifically bind to pathologic forms of calcineurin. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and methods for use of these antibodies.

公开(公告)号：US11752215B2

公开(公告)日：2023-09-12

申请号：US17200136

申请日：2021-03-12

申请人： Rutgers, The State University of New Jersey ,  Georgetown University

发明人： Siang-Yo Lin ,  Joseph R. Bertino ,  Chen-Yong Lin ,  Zoltan Szekely

IPC分类号： A61K47/68 ,  A61K47/65 ,  A61K47/60 ,  A61P35/00 ,  A61K31/40 ,  A61K31/4439 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC分类号： A61K47/6871 ,  A61K31/40 ,  A61K31/4439 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6811 ,  A61P35/00 ,  C07K16/30 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/73

摘要： The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.

公开(公告)号：US20230270876A1

公开(公告)日：2023-08-31

申请号：US18178886

申请日：2023-03-06

申请人： Novartis AG

发明人： Bernhard Hubert Geierstanger ,  Weijia Ou ,  Tetsuo Uno

IPC分类号： A61K47/68 ,  C07K16/32

CPC分类号： A61K47/6817 ,  C07K16/32 ,  A61K47/6855 ,  A61K47/6871 ,  A61K47/6803 ,  C07K16/2863

摘要： The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

公开(公告)号：US11661463B2

公开(公告)日：2023-05-30

申请号：US15750814

申请日：2016-08-05

申请人： City of Hope

发明人： Andreas Herrmann ,  Hua Yu

IPC分类号： C07K16/46 ,  A61K38/00 ,  A61K38/14 ,  A61P35/00 ,  C07K16/00 ,  C12N15/11 ,  A61K47/68 ,  A61K47/54 ,  C07K16/18 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC分类号： C07K16/468 ,  A61K38/00 ,  A61K38/14 ,  A61K47/549 ,  A61K47/6843 ,  A61K47/6851 ,  A61K47/6871 ,  A61K47/6879 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/40 ,  C12N15/11 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/622 ,  C07K2317/77 ,  C12N2310/18 ,  C12N2310/315 ,  C12N2310/3513

摘要： Provided herein are cell penetrating conjugates. The conjugates include non-cell penetrating proteins connected through a phosphorothioate nucleic acid, wherein the phosphorothioate nucleic acid enhances intracellular delivery of the non-cell penetrating proteins. Also provided are methods and kits including the conjugates provided herein.

公开(公告)号：US20180186893A1

公开(公告)日：2018-07-05

申请号：US15580713

申请日：2016-06-10

申请人： National Research Council of Canada

发明人： Anne E.G. Lenferink ,  Maureen D. O'Connor ,  Anne Marcil ,  Yves Durocher

IPC分类号： C07K16/40 ,  A61K47/68 ,  G01N33/573 ,  A61K51/10

CPC分类号： C07K16/40 ,  A61K47/6803 ,  A61K47/6871 ,  A61K51/1075 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573 ,  G01N2333/988

摘要： The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.

公开(公告)号：US20180134804A1

公开(公告)日：2018-05-17

申请号：US15710384

申请日：2017-09-20

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

发明人： David A. SCHEINBERG ,  Tao DAO ,  Cheng LIU

IPC分类号： C07K16/40 ,  A61K47/68 ,  C07K16/28

CPC分类号： C07K16/40 ,  A61K39/0011 ,  A61K47/6871 ,  C07K16/2809 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2319/70

摘要： Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.